Nebivolol Sandoz (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility, which reduces cardiac output. It also enhances nitric oxide release from the endothelium, causing vasodilation and further lowering peripheral vascular resistance.

The dose of Nebivolol Sandoz is individualized by the prescribing clinician based on the patient’s blood pressure, age, renal and hepatic function, and other medications. The prescriber determines the appropriate strength and dosing schedule.

Safety data for nebivolol in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is distinguished by its combined β1‑blockade and nitric‑oxide‑mediated vasodilation, which can provide effective blood‑pressure control with a lower incidence of metabolic side effects compared with some non‑selective beta‑blockers. It is often considered when patients need both heart‑rate reduction and vasodilation.

Nebivolol Sandoz tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep them away from moisture, heat and direct sunlight to maintain product stability.

Nebivolol Sandoz is taken orally, usually once daily with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe bradycardia, atrioventricular block, bronchospasm in patients with reactive airway disease, and rare cases of liver injury or allergic reactions. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic reaction.

Nebivolol Sandoz is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or uncontrolled asthma. It should also be used with caution in severe hepatic impairment.